Fund a Cure : Support Jansher’s Cancer Vaccine Trial

This is a story about a remarkable young man and a historic opportunity to be part of a medical miracle. Jansher Naim is a true survivor. At 19, he was diagnosed with Stage 4 fibrolamellar carcinoma (FLC), an incredibly rare liver cancer that strikes otherwise healthy children and young adults. As there are no symptoms patients are usually diagnosed at the advanced/metastatic stage. At that advanced stage the 5-year survival rate is less than 20%. After an arduous 3.5-year battle that his doctor calls “nothing short of miraculous,” Jansher has achieved a remarkable remission.

Now, he is taking an extraordinary step, not just for himself, but for humanity.

A Groundbreaking Path to a Cure

Jansher has volunteered to be a test subject in a groundbreaking clinical phase one trial for a fibrolamellar carcinoma cancer vaccine in Germany. This revolutionary treatment teaches a patient's own immune system to find and destroy the cancer by targeting its unique genetic source. It is one of the most promising scientific paths toward a true, fibrolamellar carcinoma cure, and Jansher’s participation is a critical step in making it a reality for everyone.

His motivation is deeply personal: he is fighting in memory of the friends he lost to this devastating disease and by a desire to ensure no other family suffers the same fate. As his medical director, Dr. Paul M. Kent states, “Jansher’s participation is about more than his own survival; it is about paving the way for future treatments and giving hope to families around the world.”

Why Your Support is Vital

Taking on this mission requires a monumental effort, both physically and financially. We are seeking to raise $100,000 to make it possible.

This fund is essential for three reasons:

To Fund the Mission in Germany: It will cover the direct costs of the 8 required trips to Germany for Jansher and a caregiver, including airfare, lodging, and daily expenses.

To Support His Care at Home:

To remain eligible for the trial, Jansher must maintain his complex and expensive ongoing care in the U.S. and help cover the costs of any complications that may arise from the trial

Join Us: Be Part of a Medical Miracle

Jansher is offering his courage. His doctors are offering their brilliant science. We have the opportunity to join them by offering our support. Please consider donating today to help fund this historic trial. Every contribution, no matter the size, is a step toward a future where the fibrolamellar carcinoma (FLC) vaccine is not a dream, but a reality.

Thank you for believing in this mission and in a future free from this devastating disease.

We are honored to share this powerful letter from Dr. Paul M. Kent, one of the Doctors on the team that treated Jansher and the Medical Director of the FibroFighters Foundation:

To Whom It May Concern:

I am writing on behalf of my patient, Jansher Naim, age 22 and a student at Columbia, to appeal for financial aid. As an oncology doctor, I have the privilege of caring for many remarkable patients, but few have inspired me as deeply as Jansher.

At just 19 years old, Jansher was diagnosed with a rare and aggressive liver cancer called fibrolamellar carcinoma (FLC), a disease so uncommon that it affects only about one in five million people. Jansher’s cancer was discovered at stage 4, a point at which survival rates are heartbreakingly low.

The great news is that Jansher is now in remission, for the last 31 months. This is after 16 months of chemotherapy, a 12-hour life-saving surgery, 41 cycles of immune-chemotherapy, approximately 120 days in the hospital, and, as a best guess, 1000+ blood draws. Despite these overwhelming odds and numerous doctors telling him he would die, Jansher’s resilience, positivity, and unwavering spirit have been nothing short of miraculous.

To our knowledge, Jansher is possibly one of the only stage 4 fibrolamellar survivors in New York, and among a few dozen worldwide. His remission is a testament to his extraordinary willpower. However, this cancer is notorious for its high recurrence rate.

Now, there is a groundbreaking opportunity: a phase 1 cancer vaccine trial in Germany designed specifically for FLC patients in remission, aiming to prevent the cancer from returning. His participation is not just about his own survival; it is about paving the way for future treatments and giving hope to families around the world.

- Paul M. Kent, MD, Medical Director, FibroFighters Foundation